Compare RM & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RM | IFRX |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.1M | 303.4M |
| IPO Year | 2011 | 2017 |
| Metric | RM | IFRX |
|---|---|---|
| Price | $41.65 | $1.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $30.00 | $6.25 |
| AVG Volume (30 Days) | 70.6K | ★ 1.3M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | ★ 7.49 | N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $645,598,000.00 | N/A |
| Revenue This Year | $12.94 | N/A |
| Revenue Next Year | $8.97 | N/A |
| P/E Ratio | $34.84 | ★ N/A |
| Revenue Growth | ★ 9.70 | N/A |
| 52 Week Low | $30.46 | $0.74 |
| 52 Week High | $46.00 | $2.95 |
| Indicator | RM | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.26 | 36.03 |
| Support Level | $35.76 | $0.87 |
| Resistance Level | $44.30 | $1.94 |
| Average True Range (ATR) | 1.60 | 0.15 |
| MACD | -0.28 | -0.04 |
| Stochastic Oscillator | 45.33 | 3.97 |
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. The company is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.